Alcon has acquired a majority interest in Aurion Biotech, Inc., a startup focused on innovative cell therapy for corneal endothelial disease. This acquisition comes amid a legal dispute between the two companies. Alcon has also replaced Aurion's CEO and founder, Greg Kunst, effective immediately. The acquisition is part of Alcon's strategy to expand its portfolio in the ophthalmology sector, particularly as Aurion was seeking an initial public offering (IPO). The transaction is expected to enhance Alcon's capabilities in addressing corneal diseases, which can lead to vision impairment.